GENE EXPRESSION SIGNATURES FOR STAGING AND PROGNOSIS OF PROSTATE, BREAST AND LEUKEMIA CANCERS
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Dec 25, 2014
app pub date -
Nov 21, 2012
filing date -
Nov 23, 2011
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
The present invention is drawn to methods of assessing and treating cancers such as ERG-related, prostate, breast and leukemia, by examining the expression of combinations of particular genes disregulated in this disease state. The combinations of genes are selected from the following genes: inhibitor of growth family, member 3 (HSTG3); lymphoid enhancer-binding protein factor 1 (LEF1); frizzled-related protein (FRZB); annexin A4 (ANXA4); Meis homeobox 2 (MEIS2); syndecan binding protein (syntenin) (SDCBP); ankyrin 3, node of Ranvier (ankyrin G) (ANK3); chromodomain helicase DNA binding protein 5 (CHD5); phospholipase A2, group VII (platelet-activating factor acetylhydrolase, plasma) (PLA2G7); and wingless-type MMTV integration site family member 2 (WNT2).
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully